Clinical Trial Update: A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions [Phase 3]

View source ↗

Summary

Phase 3 study evaluating a gadolinium-based contrast agent for adults undergoing MRI for known or highly suspected CNS lesions has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Central Nervous System Lesions

Snippet

Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd | Conditions: For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions | Phase 3 | Status: COMPLETED